Dihydroergotamine mesylate-loaded dissolving microneedle patch made of polyvinylpyrrolidone for management of acute migraine therapy

Taş, Çetin; Joyce, Jessica C.; Nguyen, Hiep X.; Eangoor, Padmanabhan; Knaack, Jennifer S.; Banga, Ajay K.; Prausnitz, Mark R.

doi:10.1016/j.jconrel.2017.10.021

Cited by 70 publications

(27 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Burst drug release was also possible by using highly dissolvable MN patches. Examples of this are the rapid release of acyclovir for the treatment of herpes labialis (Pamornpathomkul et al, 2018), of dihydroergotamine mesylate for the management of acute migraine (Tas et al, 2017) and of vitamin K during bleeding (Hutton et al, 2018). When targeted release was sought stimuli-responsive MN systems could offer alternatives too.…”

Section: Needle-based Transdermal Drug Delivery Devicesmentioning

confidence: 99%

Recent Advances in Micro-Electro-Mechanical Devices for Controlled Drug Release Applications

Mendoza

Scilletta

Bellino

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

In recent years, controlled release of drugs has posed numerous challenges with the aim of optimizing parameters such as the release of the suitable quantity of drugs in the right site at the right time with the least invasiveness and the greatest possible automation. Some of the factors that challenge conventional drug release include longterm treatments, narrow therapeutic windows, complex dosing schedules, combined therapies, individual dosing regimens, and labile active substance administration. In this sense, the emergence of micro-devices that combine mechanical and electrical components, so called micro-electro-mechanical systems (MEMS) can offer solutions to these drawbacks. These devices can be fabricated using biocompatible materials, with great uniformity and reproducibility, similar to integrated circuits. They can be aseptically manufactured and hermetically sealed, while having mobile components that enable physical or analytical functions together with electrical components. In this review we present recent advances in the generation of MEMS drug delivery devices, in which various micro and nanometric structures such as contacts, connections, channels, reservoirs, pumps, valves, needles, and/or membranes can be included in their design and manufacture. Implantable single and multiple reservoir-based and transdermalbased MEMS devices are discussed in terms of fundamental mechanisms, fabrication, performance, and drug release applications.

show abstract

Section: Needle-based Transdermal Drug Delivery Devicesmentioning

confidence: 99%

Recent Advances in Micro-Electro-Mechanical Devices for Controlled Drug Release Applications

Mendoza

Scilletta

Bellino

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…Despite the recommendation for annual influenza vaccinations, a significant number of people fail to get vaccinated due to their concerns about vaccine effectiveness, adverse reactions, inconvenience, and needle phobia [3,4]. Thus, a novel, cost-effective, minimally invasive, and patient-compliant delivery technology-microneedles (an array of micron-sized solid-coated or polymeric dissolving needles) could address some of these issues [5][6][7]. The Centers for Disease Control and Prevention has named this technology the potential "game changer" of global vaccination.…”

Section: Editorialmentioning

confidence: 99%

Economic Evaluation of Microneedles for Vaccinations

Nguyen¹,

Vu²,

Nguyen³

2018

J Pharmacovigil

View full text Add to dashboard Cite

“…Transdermal drug delivery studies against complex diseases and vaccination include those of Wang, et al [ 2 ] and Ye., Y. et al [ 3 ], who have loaded hyaluronic acid (HA)-based microneedles with anti-PD1 antibody, glucose oxidase (GOx)-encapsulated dextran nanoparticles, and tumor lysate, melanin, respectively, for the transdermal delivery of antitumor immune response-promoting compounds against melanoma; as well as those of Hu, et al [ 4 ], who loaded HA-based microneedles with insulin and GOx-encapsulated polymeric vesicles, and Lahiji, et al [ 5 ], who developed dissolving microneedles encapsulated with Exendin-4 hormone, against types I and II diabetes. A more comprehensive list of diseases that are treated and therapeutic compounds delivered using MN technology is presented in Table S1 [ 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 ].…”

Section: Introductionmentioning

confidence: 99%

Three-Dimensional (3D) Printed Microneedles for Microencapsulated Cell Extrusion

et al. 2018

View full text Add to dashboard Cite

Cell-hydrogel based therapies offer great promise for wound healing. The specific aim of this study was to assess the viability of human hepatocellular carcinoma (HepG2) cells immobilized in atomized alginate capsules (3.5% (w/v) alginate, d = 225 µm ± 24.5 µm) post-extrusion through a three-dimensional (3D) printed methacrylate-based custom hollow microneedle assembly (circular array of 13 conical frusta) fabricated using stereolithography. With a jetting reliability of 80%, the solvent-sterilized device with a root mean square roughness of 158 nm at the extrusion nozzle tip (d = 325 μm) was operated at a flowrate of 12 mL/min. There was no significant difference between the viability of the sheared and control samples for extrusion times of 2 h (p = 0.14, α = 0.05) and 24 h (p = 0.5, α = 0.05) post-atomization. Factoring the increase in extrusion yield from 21.2% to 56.4% attributed to hydrogel bioerosion quantifiable by a loss in resilience from 5470 (J/m3) to 3250 (J/m3), there was no significant difference in percentage relative payload (p = 0.2628, α = 0.05) when extrusion occurred 24 h (12.2 ± 4.9%) when compared to 2 h (9.9 ± 2.8%) post-atomization. Results from this paper highlight the feasibility of encapsulated cell extrusion, specifically protection from shear, through a hollow microneedle assembly reported for the first time in literature.

show abstract

Dihydroergotamine mesylate-loaded dissolving microneedle patch made of polyvinylpyrrolidone for management of acute migraine therapy

Cited by 70 publications

References 41 publications

Recent Advances in Micro-Electro-Mechanical Devices for Controlled Drug Release Applications

Recent Advances in Micro-Electro-Mechanical Devices for Controlled Drug Release Applications

Economic Evaluation of Microneedles for Vaccinations

Three-Dimensional (3D) Printed Microneedles for Microencapsulated Cell Extrusion

Contact Info

Product

Resources

About